Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer

Endokrynol Pol. 2020;71(3):283-284. doi: 10.5603/EP.a2020.0012. Epub 2020 Mar 10.

Abstract

Not required for Clinical Vignette.

Keywords: empagliflozin; euglycaemic diabetic ketoacidosis; pancreas cancer.

Publication types

  • Case Reports

MeSH terms

  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / therapeutic use
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Ketoacidosis / chemically induced*
  • Glucosides / adverse effects*
  • Glucosides / therapeutic use
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / drug therapy

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Hypoglycemic Agents
  • empagliflozin